Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Conclusion: The incidence of relapse among AML pts who have maintained CR for at least three yrs is low. However, new medical problems occur frequently, including HTN, osteoporosis, and second malignancies - with skin cancer being especially prevalent among ASCT recipients. Long-term survivors of AML require routine surveillance as well as preventative measures.Figure 1.DisclosuresKadia: Novartis: Consultancy; BMS: Research Funding; Celgene: Research Funding; Pfizer: Consultancy, Research Funding; Celgene: Research Funding; Abbvie: Consultancy; BMS: Research Funding; Takeda: Consultancy; Novartis: Consultancy; Pfizer: Consultancy, Research Funding; Abbvie: Consultancy; Jazz: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Takeda: Consultancy; Amgen: Consultancy, Research Funding. Pemmaraju: celgene: Consultancy, Honoraria; abbvie: Research Funding; cellectis: Research Funding; stemline: Consultancy, Honoraria, Research Funding; samus: Research Funding; daiichi sankyo: Research Funding; SagerStrong Foundation: Research Funding; plexxikon: Research Funding; novartis: Research Funding; Affymetrix: Research Funding. Short: Takeda Oncology: Consultancy. Daver: ImmunoGen: Consultancy; Alexion: Consultancy; Karyopharm: Consultancy; Incyte: Consultancy; Sunesis: Consultancy; Daiichi-Sankyo: Research Funding; Sunesis: Research Funding; Incyte: Research Funding; Pfizer: Research Funding; Karyopharm: Research Funding; Novartis: R...
Source: Blood - Category: Hematology Authors: Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III Source Type: research